Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 24, 2022 11:32pm
209 Views
Post# 35045701

RE:Istitutional owners

RE:Istitutional ownersI cannot tell you what plans we might have for obvious reasons. I can tell you that if new money were to come into our management, chances are we would be buyers as THTX is still in our model portfolios. If money were to leave our management, then it would depend on the client as to whether they were to hold or sell. We have had a very, very good year in 2022 as we were heavily hedged in the first half of the year,held large energy positions and have held very high levels of cash since we took the hedges off. But money comes in unexpectedly and also departs unexpectedly for all sorts of reasons so you never know how things will work out. As I have stated already in recent posts I believe THTX is a bargain right now just based on the legacy drug business and you are getting cancer and maybe NASH for free. Shareholders should do well in the medium and long term, but who knows what will happen in the short term. We are in a deep bear  market that could get even deeper and, as you can see from reading some of the posts here, people often mistake a declining share price in a bear market for real problems at the company when in actuality it is a function of real problems for shareholders (can't take the mental anguish of a falling share price and overreact by selling, get caught in a margin call or about 100 other things that can lead people to sell). On the buy side of the equation, there is only one reason to purchase shares - because you think they are going up. With insiders buying at the moment, that should calm most people's nerves but some folks do have difficulty in separatng the noise of share price declines in a bear market from the reality of good things occurring at the company.  

LouisW wrote: When i look back the institutional owners's historical transaction, i found Stewardship always had transaction in Q4 since 2014. Q4 of 2014-2019 were all BUY, 2020 and 2021 Q4 were SELL. 
So @SPCEO, do you expect Stewardship will SELL/BUY in 2022 Q4?

Interestingly, Morgan Stanley are significantly acquiring shares quaterly since 2020Q3. To me, this is a bullish signal.


<< Previous
Bullboard Posts
Next >>